Even the most effective drugs don't work if patients don't take them or if patients aren't taking the right dose. Drug adherence is one of the biggest problems that the biopharma industry faces.
Non-adherence occurs for a variety of reasons. Sometimes it is driven by pure forgetfulness, while other times patients are trying to save money when they have to pay high co-pays. Studies find that the more inconvenient a drug is to take, or the harder it is to administer, the less likely patients will adhere to the proper protocols.
In this Spotlight edition, BioPharma Dive explores the problem of drug adherence, how value-based deals with payers are rooted in patient compliance and how the problem can impact clinical trial outcomes.
We hope you enjoy reading and please provide us with any feedback. You can reach us at BioPharma Dive by Twitter or via email.
Lisa LaMotta
Editor, BioPharma Dive
E-mail
News and Trends
|
Feature Story
Rates of non-adherence vary widely and depend on the condition, price and other issues. But unfilled prescriptions and missed doses cost the healthcare system billions annually.
|
|
Feature Story
Many things can affect whether a patient takes a drug as prescribed, but stakeholders are intervening in order to make patients more compliant with their meds.
|
From pricing and value, to safety and quality, Pharma has an image problem: Innovation is the answer. Learn more
|
|
Feature Story
Drugmakers and payers are experimenting with how to align a drug's price with its value. Ensuring patient adherence is the first step to making sure the innovative deals get off the ground.
|
|
Feature Story
Making sure patients take their medications is crucial to clinical trial success, but exactly how to do that remains a daunting task for investigators.
|
|
An updated report pegs total global revenue loss at an incredible $637 billion, up nearly 13% from 2012.
|
Featured Resources
|
Patients' medication nonadherence is a $290 billion burden to our economy. It’s time for patients, caregivers, payers and the industry to work together to reduce this waste. Read more →
|
|
Ensuring innovative medicines achieve their full potential, the pharma supply chain must work harder to address medication non-adherence and improve patient outcomes. Find out how →
|
|
Poor drug adherence is a significant issue in healthcare. Simplifying medication regimens and commercializing easy-to-use dosing formats are crucial to improving outcomes of geriatric patients. Learn more →
|
What We're Reading
The New York Times
|
Popular Science
|
Washington Business Journal
|
mHealthIntelligence
|
|
